Evidence map›Paper›PMID 40653567›Full record

ArticleDiscover oncology2025

Machine learning modeling and analysis of prognostic hub genes in cervical adenocarcinoma: a multi target therapy for enhancement in immunosurveillance.

Madiha Jabeen Abbasi, Rashid Abbasi, ShuPeng Wu, Md Belal Bin Heyat, Ding Xianfeng, Huijie Jia, Aiwen Zheng

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Madiha Jabeen AbbasiSchool of Life Science and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China.
Rashid AbbasiCollege of Computer Science and Artificial Intelligent, Wenzhou University, Wenzhou, China.
ShuPeng WuSchool of Life Science and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China.
Md Belal Bin HeyatCenBRAIN Neurotech Center of Excellence, School of Engineering, Westlake University, Hangzhou, 310018, China.
Ding XianfengSchool of Life Science and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China. xfding@zstu.edu.cn.
Huijie JiaOakham School, Chapel Close Oakham, Rutland, LE15 6DT, UK.
Aiwen ZhengDepartment of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China. zhengaw@zjcc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocervical adenocarcinoma (ECA) the fatal and intrusive subtype of cervical carcinoma is on rise from the last decade. Its improper detection leads to worst clinical outcomes that urges the discovery of novel biomarkers. Therefore, we proposed insilico and invitro based approches to identify key genes that could be used as potential targeted therapies. RNA-seq and gene expression data was operated via R-programming that identified 11,592 differential expressed genes which are mainly enriched in metabolic pathways, chemical carcinogenesis-receptor activation, amoebias, MAPK and PI3K-AKT signaling pathway. Clustering modules and hub genes were retrieved to design network of immune cells with varying expression using multiple statistical algorithms. The Drugs targeting hub genes were determined from Drug gene interaction database which was further categorized for docking and dynamics based simulations. Results indicate high binding affinity of Imatinib compound into active pockets of BIRC5 which is confirmed by cell viability lab experiment. Current study demonstrates novel biomarkers and therapeutic drugs for in depth understanding of endocervical carcinogensis.

Indexed as

Endocervical adenocarcinomaFunctional enrichment analysisHub genesMolecular docking and dynamics simulationMTT AssayTumor immunosurveillance

Identifiers

PMID40653567
PMCPMC12256379

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.